Related Experiment Video

Updated: Jun 20, 2026

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
05:42

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements

Published on: January 7, 2019

Branched chain amino acids as adjunctive therapy to ketogenic diet in epilepsy: pilot study and hypothesis

Athanasios Evangeliou1, Martha Spilioti, Vai Doulioglou

  • 14th Paediatric Clinic, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece. aeevange@auth.gr

Journal of Child Neurology
|August 19, 2009
PubMed

Insights

Adding branched-chain amino acids to the ketogenic diet shows promise for treating refractory epilepsy in children. This pilot study suggests improved seizure control and diet tolerability with this combined approach.

Area of Science:

  • Neurology
  • Pediatrics
  • Nutritional Science

Background:

  • Refractory epilepsy in children poses significant treatment challenges.
  • The ketogenic diet is an established therapy but may have limitations in efficacy and tolerability.
  • Branched-chain amino acids (BCAAs) are essential nutrients with potential metabolic roles.

Purpose of the Study:

  • To investigate the role of BCAAs as an adjunctive therapy to the ketogenic diet in children with refractory epilepsy.
  • To assess the impact of BCAA supplementation on seizure reduction and ketogenic diet tolerability.

Main Methods:

  • A pilot prospective follow-up study involving 17 children (aged 2-7 years) with refractory epilepsy on the ketogenic diet.
  • Patients received additional branched-chain amino acids.
  • Changes in seizure frequency and ketosis levels were monitored.
  • The fat-to-protein ratio of the ketogenic diet was adjusted.

Main Results:

  • Significant seizure reduction was observed in 8 out of 17 patients (100% in 3, 50%-90% in 5).
  • No reduction in ketosis was recorded despite a modified fat-to-protein ratio (4:1 to 2.5:1).
  • Preliminary data suggest improved tolerability of the ketogenic diet.

Conclusions:

  • Branched-chain amino acids may enhance the effectiveness of the ketogenic diet in pediatric refractory epilepsy.
  • The combination therapy appears to improve seizure control without compromising ketosis.
  • Further research is warranted to confirm these preliminary findings and explore mechanisms.

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...